KFY Korn Ferry

Korn Ferry Futurestep Partners with GlaxoSmithKline to Support Talent Acquisition

Futurestep division of Korn Ferry (NYSE:KFY), the preeminent global people and organisational advisory firm, has been appointed by GlaxoSmithKline (NYSE:GSK), one of the world's largest science-led global healthcare companies, to provide a Flexible Delivery Solution for recruitment support across the United Kingdom, United States and Latin America.

In a desire to better respond to business requirements and to help prepare for future recruitment demand, GSK chose Futurestep to assist with hiring across its Pharmaceutical, Consumer Healthcare and Vaccines business units. Futurestep will deploy a dedicated onsite team of specialist recruiters across key locations. This will be complemented by dedicated sourcing and screening hubs within Futurestep’s Warsaw, Manchester, Bangalore and Dallas Talent Delivery Centres.

“This is an exciting opportunity to work with GSK, supporting its future growth with a tailored solution that will ensure it continues to attract outstanding talent,” said George Vollmer, Vice President, Global Accounts & Strategic Development, Futurestep. “We have worked closely with GSK’s recruitment leadership to develop a personalised approach and ensure that the solution provided supports their business goals.”

The partnership will allow GSK to leverage Futurestep’s new proprietary talent acquisition platform, bringing together a suite of best-in-class talent acquisition tools, technologies and award-winning IP, including assessment and interview capabilities. The platform will offer meaningful talent market information, as well as a streamlined approach to talent acquisition and management, whilst also improving efficiencies and enabling cost savings over time.

“We are pleased to partner with Futurestep in order to provide additional support to our recruitment teams in key markets. We look forward to learning from each other in order to deliver our objectives and provide the best experience for candidates, our hiring managers, and our teams,” commented Cindy Alisesky, Vice President of Global Recruitment, GSK. “Futurestep shared our passion for innovation and desire to build consistency, efficiency and intelligence. We are excited about the opportunity to leverage Futurestep’s platform to drive our business performance and competitiveness.”

“Life Sciences is a sector in which the battle for talent is becoming increasingly fraught; our partnership with GSK will assist them in continuing to attract top talent in this sector thereby helping to support their business,” said Kay Cooper, Vice President, Key Accounts, Futurestep. “We are exceedingly proud to be working with GSK and look forward to creating an efficient and effective solution for them.”

GSK employs diverse talent who enjoy a challenging and rewarding career unified under one mission – to improve the quality of human life by enabling people to do more, feel better, live longer. Whether working in corporate head office functions, science based disciplines such as R&D or ensuring the successful production and supply of life changing pharmaceuticals within engineering, manufacturing and supply chain, a world of opportunities is opened to ambitious, driven professionals.

Those who are interested in finding a career with purpose can apply directly on GSK website: www.gsk.com/careers

About Korn Ferry

Korn Ferry is the preeminent global people and organizational advisory firm. We help leaders, organizations and societies succeed by releasing the full power and potential of people. Our nearly 7,000 colleagues deliver services through our Executive Search, Hay Group and Futurestep divisions. Visit kornferry.com for more information.

More information on Futurestep can be found at www.kornferry.com/futurestep

About GSK

GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.

EN
21/02/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Korn Ferry

Korn Ferry: 1 director

A director at Korn Ferry sold 100,000 shares at 74.025USD and the significance rating of the trade was 79/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Valens Research
  • Valens Research

Valens Equity Insights and Inflections - D2021 10 12

LPL Financial (LPLA) has created a powerful platform to empower independent and smaller scale wealth advisors to compete with the big players like Merrill Lynch and Morgan Stanley. Uniform Accounting highlights the company's operational improvements that the market is missing, indicating equity upside. AMD Q2 2021 Embedded Expectations Analysis – Market expectations are for Uniform ROA to expand, but management may have concerns about data center revenue growth, EPYC processors, and operating c...

Valens Research
  • Valens Research

KFY - Embedded Expectations Analysis - 2021 10 05

Korn Ferry (KFY:USA) currently trades below corporate averages relative to UAFRS-based (Uniform) earnings, with a 16.8x Uniform P/E. At these levels, the market is pricing in expectations for profitability to decline to historical lows. Although management's concerns about capacity, liquidity, and operating expenses suggest the potential for near-term headwinds, longer-term equity upside remains warranted. Specifically, management may be concerned about their capacity to meet demand, the streng...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch